Thalys Medical Technology Group Inc. (603716.SS)
CNY 10.69
(3.89%)
CNY 10.69
(3.89%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -180.32 Million CNY | -564.64% |
| 2022 | 38.8 Million CNY | -72.13% |
| 2021 | 139.26 Million CNY | -32.23% |
| 2020 | 205.48 Million CNY | -19.35% |
| 2019 | 254.79 Million CNY | 60.61% |
| 2018 | 158.63 Million CNY | 14.29% |
| 2017 | 138.8 Million CNY | 46.35% |
| 2016 | 94.84 Million CNY | 14.1% |
| 2015 | 83.12 Million CNY | 9.18% |
| 2014 | 76.13 Million CNY | 12.56% |
| 2013 | 67.64 Million CNY | 29.87% |
| 2012 | 52.08 Million CNY | 3.93% |
| 2011 | 50.11 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -2.09 Million CNY | -116.78% |
| 2024 Q1 | 18.86 Million CNY | 109.59% |
| 2024 Q2 | 12.49 Million CNY | -33.77% |
| 2023 Q3 | -1.44 Million CNY | -105.09% |
| 2023 FY | -180.32 Million CNY | -564.64% |
| 2023 Q1 | -10.53 Million CNY | 94.06% |
| 2023 Q2 | 28.42 Million CNY | 369.75% |
| 2023 Q4 | -196.76 Million CNY | -13487.76% |
| 2022 Q2 | 10.43 Million CNY | -69.84% |
| 2022 Q1 | 34.59 Million CNY | 172.15% |
| 2022 FY | 38.8 Million CNY | -72.13% |
| 2022 Q4 | -177.26 Million CNY | -797.78% |
| 2022 Q3 | 25.4 Million CNY | 143.5% |
| 2021 Q2 | 15.9 Million CNY | -4.95% |
| 2021 Q3 | -886.21 Thousand CNY | -105.57% |
| 2021 Q1 | 16.73 Million CNY | -65.39% |
| 2021 FY | 139.26 Million CNY | -32.23% |
| 2021 Q4 | -47.94 Million CNY | -5310.43% |
| 2020 Q2 | 47.38 Million CNY | 301.25% |
| 2020 Q1 | -23.54 Million CNY | -220.08% |
| 2020 FY | 205.48 Million CNY | -19.35% |
| 2020 Q4 | 48.34 Million CNY | 8.01% |
| 2020 Q3 | 44.75 Million CNY | -5.54% |
| 2019 Q2 | 66.89 Million CNY | 95.68% |
| 2019 FY | 254.79 Million CNY | 60.61% |
| 2019 Q3 | 66.75 Million CNY | -0.22% |
| 2019 Q4 | 19.6 Million CNY | -70.63% |
| 2019 Q1 | 34.18 Million CNY | 3.33% |
| 2018 Q3 | 43.79 Million CNY | -10.03% |
| 2018 Q2 | 48.67 Million CNY | 47.14% |
| 2018 Q1 | 33.08 Million CNY | -42.93% |
| 2018 FY | 158.63 Million CNY | 14.29% |
| 2018 Q4 | 33.08 Million CNY | -24.44% |
| 2017 Q4 | 57.96 Million CNY | 66.94% |
| 2017 Q3 | 34.72 Million CNY | 10.78% |
| 2017 Q2 | 31.34 Million CNY | 112.25% |
| 2017 Q1 | 14.76 Million CNY | -31.59% |
| 2017 FY | 138.8 Million CNY | 46.35% |
| 2016 Q3 | 28.22 Million CNY | -20.13% |
| 2016 FY | 94.84 Million CNY | 14.1% |
| 2016 Q4 | 21.58 Million CNY | -23.5% |
| 2016 Q2 | 35.33 Million CNY | 125.02% |
| 2016 Q1 | 15.7 Million CNY | -35.04% |
| 2015 Q4 | 24.17 Million CNY | 18.5% |
| 2015 FY | 83.12 Million CNY | 9.18% |
| 2015 Q3 | 20.39 Million CNY | 0.0% |
| 2014 FY | 76.13 Million CNY | 12.56% |
| 2013 FY | 67.64 Million CNY | 29.87% |
| 2012 FY | 52.08 Million CNY | 3.93% |
| 2011 FY | 50.11 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 646.8 Million CNY | 127.879% |
| Joinn Laboratories(China)Co.,Ltd. | 507.09 Million CNY | 135.56% |
| WuXi AppTec Co., Ltd. | 11.87 Billion CNY | 101.519% |
| Autobio Diagnostics Co., Ltd. | 1.36 Billion CNY | 113.203% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 759.76 Million CNY | 123.734% |
| Chemclin Diagnostics Co., Ltd. | 166.28 Million CNY | 208.441% |